Colistin - That Was Fun, But Now We're Done

Abstract

Antimicrobial resistance (AMR) is an increasing global threat with estimates that drug-resistant infections contribute to nearly 5 million deaths worldwide every year.¹ In particular, carbapenem-resistant Acinetobacter baumannii (CRAB) is emerging as a challenging pathogen to treat and has been designated by the World Health Organization as a priority pathogen for the development of new antimicrobial agents.² Studies evaluating the efficacy of therapeutic strategies are vitally important in the fight against drug-resistant A. baumannii and other drug-resistant infections.